ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours - PubMed
3 days ago
- #consensus-framework
- #oncology
- #systemic-therapy
- ESMO developed the EnLiST framework to standardize lines of therapy (LoT) in solid tumors.
- EnLiST defines LoT for systemic anticancer therapies (SACT) in early (eLoT), advanced (aLoT), and investigational (iLoT) settings.
- A New LoT is assigned after clinical progression or inadequate response (e.g., 1.0 → 2.0).
- A Modified LoT is assigned for non-progression reasons like intolerability (e.g., 1.0 → 1.1).
- EnLiST aims to improve clinical care, research, and real-world data (RWD) standardization.
- The framework was developed via a Delphi consensus involving multiple stakeholders.